JP2012522000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522000A5 JP2012522000A5 JP2012502245A JP2012502245A JP2012522000A5 JP 2012522000 A5 JP2012522000 A5 JP 2012522000A5 JP 2012502245 A JP2012502245 A JP 2012502245A JP 2012502245 A JP2012502245 A JP 2012502245A JP 2012522000 A5 JP2012522000 A5 JP 2012522000A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidin
- phenyl
- amino
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 207
- -1 C 3-8 carbocycle Chemical group 0.000 claims 152
- 229910052739 hydrogen Inorganic materials 0.000 claims 109
- 239000001257 hydrogen Substances 0.000 claims 108
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 106
- 150000002431 hydrogen Chemical class 0.000 claims 84
- 125000001424 substituent group Chemical group 0.000 claims 82
- 229910052757 nitrogen Inorganic materials 0.000 claims 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 61
- 229910052736 halogen Inorganic materials 0.000 claims 54
- 150000002367 halogens Chemical class 0.000 claims 54
- 125000005842 heteroatom Chemical group 0.000 claims 52
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 51
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 51
- 229910052760 oxygen Inorganic materials 0.000 claims 51
- 229910052717 sulfur Inorganic materials 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims 43
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 34
- 125000004432 carbon atom Chemical group C* 0.000 claims 31
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 28
- VFNZIDKTFVKAIA-YZNLSBJPSA-N tert-butyl N-[(1R)-2-[(2S)-2-[[4-[3-(4-methoxyphenyl)-5-[[2-[(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-1-carbonyl]amino]-1H-indol-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1=CC(OC)=CC=C1C(C1=C2)=C(C=3C=CC(NC(=O)[C@H]4N(CCC4)C(=O)[C@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)=CC=3)NC1=CC=C2NC(=O)N1C(C(=O)[C@H](NC(=O)OC(C)(C)C)C=2C=CC=CC=2)CCC1 VFNZIDKTFVKAIA-YZNLSBJPSA-N 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 21
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 20
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 14
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 13
- 125000004076 pyridyl group Chemical group 0.000 claims 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 12
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 11
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 11
- 125000003386 piperidinyl group Chemical group 0.000 claims 11
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 10
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 claims 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960002429 proline Drugs 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- AEDOURZAJMSKMP-HEVIKAOCSA-N (2s)-n-[4-[3-bromo-5-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)NC2=CC=C3NC(=C(C3=C2)Br)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)CC=3C=CC=CC=3)=CC=2)CCN1C(=O)CC1=CC=CC=C1 AEDOURZAJMSKMP-HEVIKAOCSA-N 0.000 claims 3
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 3
- 125000003466 9 membered carbocyclic group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 2
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- ONQDRMAAHQRIAT-ZTJXFJJRSA-N (2S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]-N-[14-[[(2S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-18-azatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-5-yl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C(=O)NC2=CC=C3NC=4C5=CC=C(C=C5CCCC=4C3=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 ONQDRMAAHQRIAT-ZTJXFJJRSA-N 0.000 claims 1
- RNNOPRADFYFTQD-URLMMPGGSA-N (2r)-2-(dimethylamino)-1-[(2s)-2-[5-[4-(1h-indol-2-yl)phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@H](C(=O)N2[C@@H](CCC2)C=2NC(=CN=2)C=2C=CC(=CC=2)C=2NC3=CC=CC=C3C=2)N(C)C)=CC=CC=C1 RNNOPRADFYFTQD-URLMMPGGSA-N 0.000 claims 1
- RTMLENPULPASGH-PGSYEJHHSA-N (2s)-1-(2,3-diphenylpropanoyl)-n-[4-[5-[[(2s)-1-(2,3-diphenylpropanoyl)pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)NC=2C=C3C=C(NC3=CC=2)C2=CC=C(C=C2)NC(=O)[C@H]2N(CCC2)C(=O)C(CC=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C(=O)C(C=1C=CC=CC=1)CC1=CC=CC=C1 RTMLENPULPASGH-PGSYEJHHSA-N 0.000 claims 1
- ZWGFJQBNRCTGIS-HEVIKAOCSA-N (2s)-1-(2-phenylacetyl)-n-[4-[5-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-1h-pyrrolo[3,2-b]pyridin-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound N1([C@@H](CCC1)C(=O)NC=1C=CC(=CC=1)C=1NC2=CC=C(NC(=O)[C@H]3N(CCC3)C(=O)CC=3C=CC=CC=3)N=C2C=1)C(=O)CC1=CC=CC=C1 ZWGFJQBNRCTGIS-HEVIKAOCSA-N 0.000 claims 1
- HPZMZHFCAWVHHF-BCRBLDSWSA-N (2s)-1-(2-phenylacetyl)-n-[8-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-6,11-dihydro-5h-benzo[a]carbazol-3-yl]pyrrolidine-2-carboxamide Chemical compound N1([C@@H](CCC1)C(=O)NC=1C=C2CCC=3C4=CC(NC(=O)[C@H]5N(CCC5)C(=O)CC=5C=CC=CC=5)=CC=C4NC=3C2=CC=1)C(=O)CC1=CC=CC=C1 HPZMZHFCAWVHHF-BCRBLDSWSA-N 0.000 claims 1
- FVUOFOYZBNADHI-XCIZVNRNSA-N (2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]-n-[4-[5-[[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1-benzofuran-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H](N(CC)CC)C(=O)N2CCC[C@H]2C(=O)NC=2C=C3C=C(OC3=CC=2)C2=CC=C(C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 FVUOFOYZBNADHI-XCIZVNRNSA-N 0.000 claims 1
- UKJNYHDKMYFUSH-IYTFMMMVSA-N (2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]-n-[4-[5-[[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H](N(CC)CC)C(=O)N2CCC[C@H]2C(=O)NC=2C=C3C=C(NC3=CC=2)C2=CC=C(C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=CC=CC=C1 UKJNYHDKMYFUSH-IYTFMMMVSA-N 0.000 claims 1
- QUBSOKKEAIZSAQ-WPWPIJCXSA-N (2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]-n-[8-[[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-6,11-dihydro-5h-benzo[a]carbazol-3-yl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H](N(C)C)C(=O)N2CCC[C@H]2C(=O)NC2=CC=C3NC=4C5=CC=C(C=C5CCC=4C3=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 QUBSOKKEAIZSAQ-WPWPIJCXSA-N 0.000 claims 1
- ALOOORKLRZMRJL-LZCGGXSTSA-N (2s)-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]-n-[4-[5-[[(2s)-1-[(2r)-2-phenyl-2-piperidin-1-ylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound N1([C@@H](C(=O)N2CCC[C@H]2C(=O)NC=2C=C3C=C(NC3=CC=2)C2=CC=C(C=C2)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](N2CCCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCCC1 ALOOORKLRZMRJL-LZCGGXSTSA-N 0.000 claims 1
- LBXKXAKXTDJHJJ-IYTFMMMVSA-N (2s)-1-[(2r)-2-phenyl-2-pyrrolidin-1-ylacetyl]-n-[4-[5-[[(2s)-1-[(2r)-2-phenyl-2-pyrrolidin-1-ylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound N1([C@@H](C(=O)N2CCC[C@H]2C(=O)NC=2C=C3C=C(NC3=CC=2)C2=CC=C(C=C2)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](N2CCCC2)C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 LBXKXAKXTDJHJJ-IYTFMMMVSA-N 0.000 claims 1
- ZUJFKHIYUQAGAT-SMCANUKXSA-N (2s)-n-(6,11-dihydro-5h-benzo[a]carbazol-3-yl)-1-[(2s)-2-(3,3-dimethylbutanoylamino)-2-phenylacetyl]pyrrolidine-2-carboxamide Chemical compound C1([C@@H](C(=O)N2[C@@H](CCC2)C(=O)NC=2C=C3CCC=4C5=CC=CC=C5NC=4C3=CC=2)NC(=O)CC(C)(C)C)=CC=CC=C1 ZUJFKHIYUQAGAT-SMCANUKXSA-N 0.000 claims 1
- CXUIFOXMAPEXRH-ACHIHNKUSA-N (2s)-n-[4-[3-chloro-5-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)NC2=CN=C3NC(=C(C3=C2)Cl)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)CC=3C=CC=CC=3)=CC=2)CCN1C(=O)CC1=CC=CC=C1 CXUIFOXMAPEXRH-ACHIHNKUSA-N 0.000 claims 1
- MGNATTMMCLVFMH-HEVIKAOCSA-N (2s)-n-[4-[3-fluoro-5-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)NC2=CC=C3NC(=C(C3=C2)F)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)CC=3C=CC=CC=3)=CC=2)CCN1C(=O)CC1=CC=CC=C1 MGNATTMMCLVFMH-HEVIKAOCSA-N 0.000 claims 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- IKFWAKHUXARDDX-HEVIKAOCSA-N 5-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]-2-[4-[[(2s)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]phenyl]-1h-indole-3-carboxamide Chemical compound C([C@H]1C(=O)NC2=CC=C3NC(=C(C3=C2)C(=O)N)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)CC=3C=CC=CC=3)=CC=2)CCN1C(=O)CC1=CC=CC=C1 IKFWAKHUXARDDX-HEVIKAOCSA-N 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- NJQLGSSKALZLQU-JPYDVTDNSA-N CC(C)(C)OC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)-c1nc2cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC(C)(C)C)c3ccccc3)ccc2[nH]1)c1ccccc1 Chemical compound CC(C)(C)OC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)-c1nc2cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC(C)(C)C)c3ccccc3)ccc2[nH]1)c1ccccc1 NJQLGSSKALZLQU-JPYDVTDNSA-N 0.000 claims 1
- NJQLGSSKALZLQU-YKKXUYLKSA-N CC(C)(C)OC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)-c1nc2cc(NC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)ccc2[nH]1)c1ccccc1 Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)-c1nc2cc(NC(=O)[C@@H]3CCCN3C(=O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)ccc2[nH]1)c1ccccc1 NJQLGSSKALZLQU-YKKXUYLKSA-N 0.000 claims 1
- RZFPNUBKDXDHCW-JPYDVTDNSA-N CN[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2[nH]c(cc2c1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](NC)c1ccccc1)c1ccccc1 Chemical compound CN[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2[nH]c(cc2c1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](NC)c1ccccc1)c1ccccc1 RZFPNUBKDXDHCW-JPYDVTDNSA-N 0.000 claims 1
- RZFPNUBKDXDHCW-YKKXUYLKSA-N CN[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2[nH]c(cc2c1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC)c1ccccc1)c1ccccc1 Chemical compound CN[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2[nH]c(cc2c1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC)c1ccccc1)c1ccccc1 RZFPNUBKDXDHCW-YKKXUYLKSA-N 0.000 claims 1
- GXDIOGAPVJEFJL-UWXQCODUSA-N N1([C@@H](CCC1)C(=O)NC=1C=C2CCCC=3C4=CC(NC(=O)[C@H]5N(CCC5)C(=O)CC=5C=CC=CC=5)=CC=C4NC=3C2=CC=1)C(=O)CC1=CC=CC=C1 Chemical compound N1([C@@H](CCC1)C(=O)NC=1C=C2CCCC=3C4=CC(NC(=O)[C@H]5N(CCC5)C(=O)CC=5C=CC=CC=5)=CC=C4NC=3C2=CC=1)C(=O)CC1=CC=CC=C1 GXDIOGAPVJEFJL-UWXQCODUSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000005130 benzoxazines Chemical class 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- DIQKICKSJXHDFL-YZBUDRBASA-N benzyl (2s)-2-[5-[4-[5-[[(2s)-1-[(2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]-1h-imidazol-2-yl]pyrrolidine-1-carboxylate Chemical compound C([C@H]1C2=NC=C(N2)C2=CC=C(C=C2)C=2NC3=CC=C(C=C3C=2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)OC(C)(C)C)C=2C=CC=CC=2)CCN1C(=O)OCC1=CC=CC=C1 DIQKICKSJXHDFL-YZBUDRBASA-N 0.000 claims 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- HKKYCBGKXPTMPI-IOWSJCHKSA-N n-[4-[5-[5-[(2s)-1-[(2r)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3,4-oxadiazol-2-yl]-1h-indol-2-yl]phenyl]acetamide Chemical compound O1C([C@@H]2CCCN2C(=O)[C@H](N(CC)CC)C=2C=CC=CC=2)=NN=C1C(C=C1C=2)=CC=C1NC=2C1=CC=C(NC(C)=O)C=C1 HKKYCBGKXPTMPI-IOWSJCHKSA-N 0.000 claims 1
- JIQHLXQULYNGBC-IYTFMMMVSA-N propan-2-yl N-[(1R)-2-oxo-1-phenyl-2-[(2S)-2-[2-[4-[5-[[(2S)-1-[(2R)-2-phenyl-2-(propan-2-yloxycarbonylamino)acetyl]pyrrolidine-2-carbonyl]amino]-1H-indol-2-yl]phenyl]-1H-imidazol-5-yl]pyrrolidin-1-yl]ethyl]carbamate Chemical compound C1([C@@H](NC(=O)OC(C)C)C(=O)N2CCC[C@H]2C2=CN=C(N2)C2=CC=C(C=C2)C=2NC3=CC=C(C=C3C=2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)OC(C)C)C=2C=CC=CC=2)=CC=CC=C1 JIQHLXQULYNGBC-IYTFMMMVSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WEDWSADPODEZSW-ATUXXYJQSA-N tert-butyl N-[(1R)-2-[(2S)-2-[6-[5-[[(2S)-1-[(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1H-indol-2-yl]-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2[nH]c(cc2c1)-c1ccc2[nH]c(nc2c1)[C@@H]1CCCN1C(=O)[C@H](NC(=O)OC(C)(C)C)c1ccccc1)c1ccccc1 WEDWSADPODEZSW-ATUXXYJQSA-N 0.000 claims 1
- DJHDQHHSWXTPOL-DUBDIQTKSA-N tert-butyl N-[(1R)-2-[(2S)-2-[[4-[3-(cyclopropylcarbamoyl)-5-[[(2S)-1-[(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1H-indol-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1([C@@H](NC(=O)OC(C)(C)C)C(=O)N2CCC[C@H]2C(=O)NC2=CC=C3NC(=C(C3=C2)C(=O)NC2CC2)C2=CC=C(C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)OC(C)(C)C)C=2C=CC=CC=2)=CC=CC=C1 DJHDQHHSWXTPOL-DUBDIQTKSA-N 0.000 claims 1
- AJYSXMGBBDTTAW-SKQWTEPWSA-N tert-butyl n-[(1r)-2-[(2s)-2-[[2-[4-[2-[(2s)-1-[(2r)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]-1h-indol-5-yl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1([C@@H](NC(=O)OC(C)(C)C)C(=O)N2CCC[C@H]2C(=O)NC=2C=C3C=C(NC3=CC=2)C2=CC=C(C=C2)C2=CN=C(N2)[C@@H]2CCCN2C(=O)[C@H](N(C)C)C=2C=CC=CC=2)=CC=CC=C1 AJYSXMGBBDTTAW-SKQWTEPWSA-N 0.000 claims 1
- WOXPSJXHTJZPDJ-ODTVBPJYSA-N tert-butyl n-[(1r)-2-[(2s)-2-[[2-[4-[[(2s)-1-acetylpyrrolidine-2-carbonyl]amino]phenyl]-3-fluoro-1h-indol-5-yl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound CC(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C2=C(C3=CC(NC(=O)[C@H]4N(CCC4)C(=O)[C@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)=CC=C3N2)F)C=C1 WOXPSJXHTJZPDJ-ODTVBPJYSA-N 0.000 claims 1
- OOASIBIGISWJFA-GMCHKSTQSA-N tert-butyl n-[(1r)-2-[(2s)-2-[[3-fluoro-2-[4-(2-oxopyrrolidin-1-yl)phenyl]-1h-indol-5-yl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound O=C([C@@H]1CCCN1C(=O)[C@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)NC(C=C1C=2F)=CC=C1NC=2C(C=C1)=CC=C1N1CCCC1=O OOASIBIGISWJFA-GMCHKSTQSA-N 0.000 claims 1
- XUIIRTRGXIYKBA-PHSYWDIOSA-N tert-butyl n-[(1r)-2-[(2s)-2-[[4-[3-(3-methylphenyl)-5-[[(2s)-1-[(2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound CC1=CC=CC(C=2C3=CC(NC(=O)[C@H]4N(CCC4)C(=O)[C@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)=CC=C3NC=2C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)=CC=2)=C1 XUIIRTRGXIYKBA-PHSYWDIOSA-N 0.000 claims 1
- ISVODORPOXOXSK-FIBWVYCGSA-N tert-butyl n-[(1s)-2-[(2s)-2-[[2-(4-acetamidophenyl)-3-chloro-1h-indol-5-yl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1=CC(NC(=O)C)=CC=C1C1=C(Cl)C2=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)=CC=C2N1 ISVODORPOXOXSK-FIBWVYCGSA-N 0.000 claims 1
- XTZCHOMMYCPWKW-VMPREFPWSA-N tert-butyl n-[(1s)-2-[(2s)-2-[[4-(5-cyano-1h-indol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1([C@@H](C(=O)N2[C@@H](CCC2)C(=O)NC=2C=CC(=CC=2)C=2NC3=CC=C(C=C3C=2)C#N)NC(=O)OC(C)(C)C)=CC=CC=C1 XTZCHOMMYCPWKW-VMPREFPWSA-N 0.000 claims 1
- IKOODQHLWDYOCK-MXAOVZPPSA-N tert-butyl n-[(1s)-2-[(2s)-2-[[4-[3-fluoro-5-[[(2s)-1-[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetyl]pyrrolidine-2-carbonyl]amino]-1h-indol-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate Chemical compound C1([C@H](NC(=O)OC(C)(C)C)C(=O)N2CCC[C@H]2C(=O)NC2=CC=C3NC(=C(C3=C2)F)C2=CC=C(C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC(C)(C)C)C=2C=CC=CC=2)=CC=CC=C1 IKOODQHLWDYOCK-MXAOVZPPSA-N 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 0 NC(*(CCC1)C1O)=O Chemical compound NC(*(CCC1)C1O)=O 0.000 description 14
- ZGMWGSBSLHOATG-UHFFFAOYSA-N CC1=CC(CN)=CCC1 Chemical compound CC1=CC(CN)=CCC1 ZGMWGSBSLHOATG-UHFFFAOYSA-N 0.000 description 1
- AIICVSNLYYSSLG-UHFFFAOYSA-O CC=C(C)OC([NH2+]C)=C Chemical compound CC=C(C)OC([NH2+]C)=C AIICVSNLYYSSLG-UHFFFAOYSA-O 0.000 description 1
- WXYDHDWIJKEYEB-UHFFFAOYSA-N CCC1N(C)C1 Chemical compound CCC1N(C)C1 WXYDHDWIJKEYEB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16395809P | 2009-03-27 | 2009-03-27 | |
| US61/163,958 | 2009-03-27 | ||
| US24731809P | 2009-09-30 | 2009-09-30 | |
| US61/247,318 | 2009-09-30 | ||
| PCT/US2010/028653 WO2010111483A1 (en) | 2009-03-27 | 2010-03-25 | Inhibitors of hepatitis c virus replication |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014195016A Division JP5932929B2 (ja) | 2009-03-27 | 2014-09-25 | Ｃ型肝炎ウイルス複製の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522000A JP2012522000A (ja) | 2012-09-20 |
| JP2012522000A5 true JP2012522000A5 (enExample) | 2013-02-07 |
| JP5913091B2 JP5913091B2 (ja) | 2016-04-27 |
Family
ID=42781502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502245A Active JP5913091B2 (ja) | 2009-03-27 | 2010-03-25 | Ｃ型肝炎ウイルス複製の阻害剤 |
| JP2014195016A Active JP5932929B2 (ja) | 2009-03-27 | 2014-09-25 | Ｃ型肝炎ウイルス複製の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014195016A Active JP5932929B2 (ja) | 2009-03-27 | 2014-09-25 | Ｃ型肝炎ウイルス複製の阻害剤 |
Country Status (40)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
| RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| SG10201402969QA (en) * | 2009-03-27 | 2014-09-26 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5734956B2 (ja) | 2009-04-15 | 2015-06-17 | アッヴィ・インコーポレイテッド | 抗ウィルス化合物 |
| AU2010249080A1 (en) | 2009-05-12 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| NZ619205A (en) | 2009-05-13 | 2015-04-24 | Gilead Pharmasset Llc | Antiviral compounds |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| EP2435424B1 (en) | 2009-05-29 | 2015-01-21 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| PL2368890T3 (pl) | 2009-06-11 | 2013-10-31 | Abbvie Bahamas Ltd | Inhibitory wirusa zapalenia wątroby C |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| NZ597982A (en) | 2009-09-04 | 2013-01-25 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS for treating Hepatitis C virus |
| WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| BR112012006630A2 (pt) * | 2009-09-24 | 2016-05-03 | Hoffmann La Roche | derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012008658A (es) | 2010-01-25 | 2012-12-05 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c. |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| BR112012022311A2 (pt) | 2010-03-04 | 2016-08-23 | Enanta Pharm Inc | agentes farmacêuticos de combinação como inibidores da replicação de hcv. |
| BR112012022125A2 (pt) * | 2010-03-09 | 2016-11-01 | Merck Sharp & Dhme Corp | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente |
| JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
| US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012006060A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| AU2011276526A1 (en) | 2010-06-28 | 2013-01-10 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| EP2606041A2 (en) | 2010-08-17 | 2013-06-26 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| CA2809261A1 (en) * | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| AU2011314168A1 (en) * | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012040923A1 (en) * | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| JP2013544232A (ja) * | 2010-09-29 | 2013-12-12 | メルク・シャープ・エンド・ドーム・コーポレイション | 多環式複素環誘導体ならびにウィルス疾患の治療のための方法およびそれの使用 |
| EP2621931A4 (en) * | 2010-09-29 | 2014-03-19 | Merck Sharp & Dohme | TETRAZYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
| CN103459399A (zh) * | 2010-09-29 | 2013-12-18 | 默沙东公司 | 用于治疗丙型肝炎病毒感染的四环吲哚衍生物 |
| WO2012083048A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| US8835456B1 (en) | 2011-03-18 | 2014-09-16 | Achillion Pharmaceuticals, Inc. | NS5A inhibitors useful for treating HCV |
| EA201391519A1 (ru) | 2011-04-13 | 2014-03-31 | Мерк Шарп И Доум Корп. | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
| PH12013502455A1 (en) | 2011-05-27 | 2014-01-20 | Achillion Pharmaceuticals Inc | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
| EP2730572B1 (en) * | 2011-07-09 | 2015-09-16 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| TW201313697A (zh) | 2011-07-26 | 2013-04-01 | Vertex Pharma | 製備噻吩化合物之方法 |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| KR101326828B1 (ko) | 2011-12-07 | 2013-11-11 | 현대자동차주식회사 | 클램핑 장치용 회전모듈 |
| KR20140104030A (ko) * | 2011-12-16 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | Hcv ns5a의 억제제 |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| EP2887804B1 (en) | 2012-05-22 | 2021-01-27 | Trustees of Dartmouth College | Cycloalkanyl[b]indoles useful as glp-1 modulators |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| WO2014059901A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| KR20150070290A (ko) * | 2012-10-17 | 2015-06-24 | 에프. 호프만-라 로슈 아게 | Trp 채널 길항제로서의 6-아미노인돌 유도체 |
| WO2014059902A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| RU2015123641A (ru) | 2012-11-19 | 2017-01-10 | Мерк Шарп И Доум Корп. | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний |
| CN103848818B (zh) | 2012-11-29 | 2017-03-15 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用 |
| WO2014082379A1 (en) | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co.,Ltd. | Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention |
| WO2014110688A1 (en) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| UA118256C2 (uk) | 2013-01-31 | 2018-12-26 | Гіліад Фармассет Елелсі | Комбінований склад двох противірусних сполук |
| WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| WO2014140077A1 (en) | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN105837561B (zh) * | 2013-06-06 | 2019-06-28 | 上海爱博医药科技有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| WO2014205592A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof for treatment of hepatitis c |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US9725464B2 (en) | 2013-10-30 | 2017-08-08 | Merck Sharp & Dohme Corp. | Process for preparing tetracyclic heterocycle compounds |
| US10167298B2 (en) | 2013-10-30 | 2019-01-01 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| CN104860935A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途 |
| EP3145932B1 (en) * | 2014-05-21 | 2018-08-15 | Bristol-Myers Squibb Company | 2-(aryl- or heteroaryl-)phenyl (aza)benzofuran compounds for the treatment of hepatitis c |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| WO2016004899A1 (en) * | 2014-07-11 | 2016-01-14 | Merck Sharp & Dohme Corp. | Process for making tetracyclic heterocycle compounds |
| EP3237412A4 (en) * | 2014-12-22 | 2018-10-17 | Merck Sharp & Dohme Corp. | Solid dispersion formulations of antiviral compounds |
| US10239845B2 (en) | 2015-02-02 | 2019-03-26 | Forma Therapeutics, Inc. | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| WO2016196932A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Process for preparing substituted tetracyclic heterocycle compounds |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN108349945B (zh) * | 2015-11-06 | 2021-10-29 | 江苏豪森药业集团有限公司 | Hcv抑制剂、其制备方法与应用 |
| CA3010847C (en) * | 2016-02-19 | 2025-09-23 | Pmv Pharmaceuticals Inc | Methods and compounds for restoring mutant p53 function |
| WO2017181383A1 (en) | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| EP3471737B1 (en) | 2016-06-20 | 2025-06-04 | Merck Sharp & Dohme LLC | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| JP6958797B2 (ja) | 2016-06-21 | 2021-11-02 | 浙江柏拉阿図医薬科技有限公司 | Ｃ型肝炎ウイルス阻害剤およびその使用 |
| WO2018032468A1 (en) | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| WO2018032467A1 (en) | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases |
| KR101887969B1 (ko) * | 2016-08-30 | 2018-08-13 | 한국과학기술연구원 | 항바이러스 활성을 가지는 카르바졸 화합물 |
| CN109134600B (zh) * | 2017-06-19 | 2021-07-20 | 杭州国谋生物科技有限公司 | 作为丙型肝炎抑制剂的烷基及杂环化合物及其在药物中的应用 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109232612A (zh) * | 2017-07-11 | 2019-01-18 | 周龙兴 | 抑制丙肝病毒的化合物、药物组合物及其用途 |
| WO2019057946A1 (en) | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
| WO2020247736A1 (en) * | 2019-06-07 | 2020-12-10 | University Of Massachusetts | Hepatitis c virus ns3/4a protease inhibitors |
| ES3040401T3 (en) | 2019-09-23 | 2025-10-30 | Pmv Pharmaceuticals Inc | Methods and compounds for restoring mutant p53 function |
| CA3183081A1 (en) | 2020-06-24 | 2021-12-30 | Arnold Levine | Combination therapy for treatment of cancer |
| KR20240012476A (ko) | 2021-05-21 | 2024-01-29 | 길리애드 사이언시즈, 인코포레이티드 | 지카 바이러스 저해제로서의 펜타사이클릭 유도체 |
| EP4637749A2 (en) * | 2022-12-19 | 2025-10-29 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| CN117362162A (zh) * | 2023-08-30 | 2024-01-09 | 中国科学院大连化学物理研究所 | 一种羰基类化合物的制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH478208A (de) * | 1965-08-05 | 1969-09-15 | Sandoz Ag | Verfahren zur Herstellung von Perinonfarbstoffen |
| JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
| WO2002024667A1 (en) * | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| CA2531511A1 (en) | 2003-07-10 | 2005-01-20 | Paradigm Therapeutics Ltd. | Silicon compounds and their use |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| JP2008517986A (ja) | 2004-10-26 | 2008-05-29 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス薬としての四環式インドール誘導体 |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US7994360B2 (en) * | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| US20110104109A1 (en) | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| WO2007009120A2 (en) * | 2005-07-14 | 2007-01-18 | Irm Llc | Heterotetracyclic compounds as tpo mimetics |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| FR2894963A1 (fr) | 2005-12-16 | 2007-06-22 | Inst Nat Sante Rech Med | Nouveaux composes interagissant avec pea-15 |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AU2008284304A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Silicon derivatives as histone deacetylase inhibitors |
| TW200922569A (en) | 2007-08-10 | 2009-06-01 | Genelabs Tech Inc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| CA2715839C (en) | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| SI2310095T1 (sl) | 2008-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji |
| WO2010041687A1 (ja) * | 2008-10-09 | 2010-04-15 | コニカミノルタホールディングス株式会社 | 有機光電変換素子、太陽電池及び光センサアレイ |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| PE20120124A1 (es) * | 2008-12-03 | 2012-03-17 | Presidio Pharmaceuticals Inc | Derivados 2-pirrolidin-3-il-1h-imidazol, como inhibidores de la proteina no estructural 5a del virus de la heptitis c |
| AU2010229795A1 (en) | 2009-03-27 | 2011-10-13 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
| SG10201402969QA (en) * | 2009-03-27 | 2014-09-26 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2516430B1 (en) | 2009-12-22 | 2014-11-05 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| BR112012022125A2 (pt) | 2010-03-09 | 2016-11-01 | Merck Sharp & Dhme Corp | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente |
| JP2013541499A (ja) | 2010-07-26 | 2013-11-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法 |
| JP2013544232A (ja) * | 2010-09-29 | 2013-12-12 | メルク・シャープ・エンド・ドーム・コーポレイション | 多環式複素環誘導体ならびにウィルス疾患の治療のための方法およびそれの使用 |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| AU2011314168A1 (en) | 2010-09-29 | 2013-04-04 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
-
2010
- 2010-03-25 SG SG10201402969QA patent/SG10201402969QA/en unknown
- 2010-03-25 BR BRPI1013394-1A patent/BRPI1013394B1/pt active IP Right Grant
- 2010-03-25 HU HUE10756840A patent/HUE027755T2/en unknown
- 2010-03-25 KR KR1020117025316A patent/KR101387274B1/ko active Active
- 2010-03-25 UA UAA201112538A patent/UA108351C2/ru unknown
- 2010-03-25 CN CN201811052267.XA patent/CN109651342A/zh active Pending
- 2010-03-25 PE PE2011001718A patent/PE20120765A1/es active IP Right Grant
- 2010-03-25 CA CA2756172A patent/CA2756172C/en active Active
- 2010-03-25 SG SG2011069887A patent/SG174929A1/en unknown
- 2010-03-25 WO PCT/US2010/028653 patent/WO2010111483A1/en not_active Ceased
- 2010-03-25 GE GEAP201012428A patent/GEP20146134B/en unknown
- 2010-03-25 ES ES10756840.4T patent/ES2573088T3/es active Active
- 2010-03-25 AU AU2010229833A patent/AU2010229833B2/en not_active Ceased
- 2010-03-25 MA MA34270A patent/MA33209B1/fr unknown
- 2010-03-25 NZ NZ595410A patent/NZ595410A/en not_active IP Right Cessation
- 2010-03-25 CN CN201410127412.1A patent/CN103880862B/zh active Active
- 2010-03-25 RS RS20160286A patent/RS54713B1/sr unknown
- 2010-03-25 MX MX2011010084A patent/MX2011010084A/es active IP Right Grant
- 2010-03-25 PL PL10756840T patent/PL2410844T3/pl unknown
- 2010-03-25 HR HRP20160476TT patent/HRP20160476T1/hr unknown
- 2010-03-25 JP JP2012502245A patent/JP5913091B2/ja active Active
- 2010-03-25 SI SI201031173A patent/SI2410844T1/sl unknown
- 2010-03-25 CN CN201080021629.4A patent/CN102427729B/zh active Active
- 2010-03-25 KR KR1020137031213A patent/KR20130140219A/ko not_active Withdrawn
- 2010-03-25 DK DK10756840.4T patent/DK2410844T3/en active
- 2010-03-25 EP EP10756840.4A patent/EP2410844B1/en active Active
- 2010-03-25 MY MYPI2013004468A patent/MY169311A/en unknown
- 2010-03-25 US US13/260,684 patent/US8871759B2/en active Active
- 2010-03-25 EA EA201171174A patent/EA020898B1/ru active Protection Beyond IP Right Term
- 2010-03-25 ME MEP-2016-84A patent/ME02418B/me unknown
-
2011
- 2011-09-11 IL IL215094A patent/IL215094A/en active IP Right Grant
- 2011-09-19 ZA ZA2011/06807A patent/ZA201106807B/en unknown
- 2011-09-21 TN TN2011000475A patent/TN2011000475A1/fr unknown
- 2011-09-23 NI NI201100172A patent/NI201100172A/es unknown
- 2011-09-23 CO CO11124967A patent/CO6420390A2/es active IP Right Grant
- 2011-09-26 DO DO2011000298A patent/DOP2011000298A/es unknown
- 2011-09-27 CR CR20110506A patent/CR20110506A/es unknown
- 2011-09-28 EC EC2011011357A patent/ECSP11011357A/es unknown
-
2013
- 2013-12-17 ZA ZA2013/09504A patent/ZA201309504B/en unknown
-
2014
- 2014-08-29 US US14/473,117 patent/US9090661B2/en active Active
- 2014-09-25 JP JP2014195016A patent/JP5932929B2/ja active Active
-
2015
- 2015-05-13 US US14/711,345 patent/US20150246917A1/en not_active Abandoned
-
2016
- 2016-09-22 US US15/272,669 patent/US20170008906A1/en not_active Abandoned
- 2016-12-26 FR FR16C1026C patent/FR16C1026I2/fr active Active
- 2016-12-29 LT LTPA2016048C patent/LTC2410844I2/lt unknown
- 2016-12-30 NL NL300858C patent/NL300858I2/nl unknown
-
2017
- 2017-01-03 LU LU00003C patent/LUC00003I2/fr unknown
- 2017-01-10 HU HUS1700002C patent/HUS1700002I1/hu unknown
- 2017-01-20 NO NO2017006C patent/NO2017006I2/no unknown
- 2017-01-20 CY CY2017004C patent/CY2017004I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522000A5 (enExample) | ||
| JP7620649B2 (ja) | コロナウイルス、ピコルナウイルス及びノロウイルス感染を治療するための抗ウイルス化合物 | |
| KR101492672B1 (ko) | Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸 | |
| US8871759B2 (en) | Inhibitors of hepatitis C virus replication | |
| KR101730681B1 (ko) | Ｃ형 간염 바이러스 억제제 | |
| JP2013510853A5 (enExample) | ||
| KR101468765B1 (ko) | Ｃ형 간염 바이러스 억제제 | |
| JP5612612B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2012518000A5 (enExample) | ||
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2010500413A5 (enExample) | ||
| ME02201B (me) | Pripravci u krutom stanju | |
| RU2010130095A (ru) | Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента | |
| RU2010109895A (ru) | Соединения индола в качестве ингибиторов клеточного некроза | |
| HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2014506877A5 (enExample) | ||
| NZ606645A (en) | Anti-viral compounds | |
| JP2014513690A5 (enExample) | ||
| JP2014133739A5 (enExample) | ||
| CA2594667A1 (en) | Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid | |
| RU2013124814A (ru) | Гетероциклические производные диазенийдиолата | |
| JP2017527628A5 (enExample) | ||
| US11053243B2 (en) | Inhibitors of hepatitis C virus replication | |
| JPWO2021148420A5 (enExample) | ||
| JP2025097322A5 (enExample) |